SEC Form 4 · accession 0001179110-18-012267
Esperion Therapeutics, Inc. · ESPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roger S Newton
Director
Period of report
Oct 16, 2018
Accepted (ET)
Oct 18, 2018 · 5:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434868
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 16, 2018 | S | 9,400 | $50.01 | D | 589,326 | D | |
| Common StockF1,F3 | Oct 17, 2018 | S | 12,673 | $50.02 | D | 576,653 | D | |
| Common StockF1 | Oct 18, 2018 | S | 100 | $50.00 | D | 576,553 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 21, 2018.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.08, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.16, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4